Abstract
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder representing the most common form of dementia and the most feared highly disabling age-related condition of our time. Hallmarks of AD include a dramatically increasing number of cases due to prospected demographics and the absence of a cure. AD is incurable as it escapes the formula “one disease, one mechanism, one drug”. AD has a multifaceted pathophysiology only in part uncovered. Even the proven chronological primacy of free radical-related damage in AD-related neurodegeneration has not yield successful oxidative stress – lowering trial designs. As a consequence, clinical trials of antioxidants in AD have brought largely negative conclusions. The aims of this review are to discuss 1. rationale for antioxidant trials, 2. reasons for failure of antioxidants in AD therapy, 3. potential preventive benefits of natural nutrition against AD onset and 4. the enormous relevance of detecting and treating AD risk factors as long as possible prior to AD manifestation.
Keywords: Clinical trial, antioxidant, oxidative stress, free radical, Alzheimer's disease, mild cognitive impairment.
Current Pharmaceutical Design
Title:Antioxidant Clinical Trials in Mild Cognitive Impairment and Alzheimer’s disease – Challenges and Perspectives
Volume: 20 Issue: 18
Author(s): Maria Cristina Polidori and Gereon Nelles
Affiliation:
Keywords: Clinical trial, antioxidant, oxidative stress, free radical, Alzheimer's disease, mild cognitive impairment.
Abstract: Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder representing the most common form of dementia and the most feared highly disabling age-related condition of our time. Hallmarks of AD include a dramatically increasing number of cases due to prospected demographics and the absence of a cure. AD is incurable as it escapes the formula “one disease, one mechanism, one drug”. AD has a multifaceted pathophysiology only in part uncovered. Even the proven chronological primacy of free radical-related damage in AD-related neurodegeneration has not yield successful oxidative stress – lowering trial designs. As a consequence, clinical trials of antioxidants in AD have brought largely negative conclusions. The aims of this review are to discuss 1. rationale for antioxidant trials, 2. reasons for failure of antioxidants in AD therapy, 3. potential preventive benefits of natural nutrition against AD onset and 4. the enormous relevance of detecting and treating AD risk factors as long as possible prior to AD manifestation.
Export Options
About this article
Cite this article as:
Polidori Cristina Maria and Nelles Gereon, Antioxidant Clinical Trials in Mild Cognitive Impairment and Alzheimer’s disease – Challenges and Perspectives, Current Pharmaceutical Design 2014; 20 (18) . https://dx.doi.org/10.2174/13816128113196660706
DOI https://dx.doi.org/10.2174/13816128113196660706 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vulnerable Plaque Versus Vulnerable Patient: Emerging Blood Biomarkers for Risk Stratification
Endocrine, Metabolic & Immune Disorders - Drug Targets Purines as Neurotransmitters and Neuromodulators in Blood Vessels
Current Vascular Pharmacology bmp3 is Required for Integrity of Blood Brain Barrier by Promoting Pericyte Coverage in Zebrafish Embryos
Current Molecular Medicine Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update
Current Vascular Pharmacology Editorial (Thematic Issue: Antithrombotic Therapy: Current and Future Clinical Use)
Current Vascular Pharmacology Medicinal Chemistry of Antimigraine Drugs
Current Medicinal Chemistry Photosensitizers for Photodynamic Therapy: Photochemistry in the Service of Oncology
Current Pharmaceutical Design Adonis sp., Convallaria sp., Strophanthus sp., Thevetia sp., and Leonurus sp. - Cardiotonic Plants with Known Traditional Use and a Few Preclinical and Clinical Studies
Current Pharmaceutical Design A Population-Based Study of Cholesterol Measurements in the Oldest Old
Current Aging Science CYLD-Mediated Signaling and Diseases
Current Drug Targets Achilles Tendon in Diabetes
Current Diabetes Reviews Therapeutic Targeting of Endothelial Dysfunction in Chronic Diabetic Complications
Recent Patents on Cardiovascular Drug Discovery Nutritional Assessment in the Critically Ill Child
Current Pediatric Reviews The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Current Pharmaceutical Design Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Current Pharmaceutical Design Editorial (Thematic Issue: Combination Therapy of Vascular Diseases and Fangjiomics: When West Meets East in the Era of Phenomics)
Current Vascular Pharmacology The Role of β-Amyloid Protein in Synaptic Function: Implications for Alzheimers Disease Therapy
Current Neuropharmacology Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Cardiovascular & Hematological Disorders-Drug Targets